drugset / Trial / NCT03311464

A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan

NCT03311464

Phase 3 Completed 22 enrolled AbbVie
NaSingle-groupOpen-labelTreatment

Summary

This study is designed to investigate the efficacy, safety and pharmacokinetics of adalimumab in subjects in Japan with active ulcer(s) due to Pyoderma Gangrenosum (PG).

Timeline

Start
2017-10-27
Primary completion
2019-08-20
Completion
2020-04-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Adalimumab Monoclonal antibody Subcutaneous

Indications